Adult participants aged 18 years or older with mild-to-moderate facial seborrheic dermatitis seborrheic dermatitis, ectoine, hydrocortisone, SEDASI, randomised controlled trial
Conditions
Interventions
7% Ectoine cream apply twice daily,1%Hydrocortisone cream apply twice daily
Experimental Drug,Experimental Drug
7% Ectoine cream,1%Hydrocortisone cream
Sponsors
Qualimed Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.18 years old or older 2.Mild to moderate facial Seborrheic dermatitis (SEDASI = 1-29) 3.Participate in the project voluntarily and sign the consent 4.Able to follow-up examination 5.Patient who complete treatment in active phase of the project and IGA 0 or 1
Exclusion criteria
Exclusion criteria: 1.Allergy to glucocorticoid/ingredient in ectoine cream 2.Pregnancy or lactation 3.Severe facial seborrheic dermatitis 4.Facial skin infection e.g. Bacteria, virus or fungal Other dermatology disease e.g. Acne (moderate to severe), dermatitis, rosacea, psoriasis Immunocompromised Treatment of Seborrheic dermatitis in 4 weeks before participate the project (Topical steroid and drug, Topical Antifungal and drug, Topical calcineurin inhibitor, Isotretinoin)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seborrheic Dermatitis Area and Severity Index 4weeks severity score | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigator Global Assessment 4 weeks severity score,Patient Global Assessment 4 weeks severity score,Remission rate 4 weeks rate,Time to remission 4 weeks days | — |
Countries
Thailand
Contacts
Public ContactMontree Udompataikul
Department of Dermatology, Faculty of Medicine, Srinakharinwirot University
Outcome results
None listed